RESULTS

RESULTS

Table(1):Comparison between fibroid and controls as regara age, gravidity , parity, abortion, menopausal state and oral contraceptive pill using.

	Study cases (n=22)		Controls (n=12)		Significance	
	Mean	± SD	Mean	±SD	t	p
Age	45.23	± 3.25	46.75	± 4.29	1.17	>0.05
Gravidity	5.00	± 1.83	5.50	± 1.62	0.79	>0.05
Parity	4.32	± 1.39	4.92	± 1.44	1.18	>0.05
Abortion	0.68	± 0.72	0.58	± 0.79	0.37	>0.05
	No.	%	No.	%	Fisher	p
Menopause						
pre	22	100.0	9	75.0		<0.05*
post	0	0.0	3	25.0		

There is statistically insignificant difference between study cases and controls as regard age, gravidity, parity and abortion but there is statistically significant difference between study cases controls as regard menopausal state.

Fig.(1):The mean age± SD in the study and control groups.



Fig.(2):The mean parity± SD in the study and control groups



Table(2): Comparison between fibroird cases and controls as regards pathology.

Menstrual phase	*Study Cases (N=22)*		*Controls (N=12)*	
	No.	*%*	*No.*	*%*
Leiomyoma	*22*	*100.0*	*0*	*0.0*
Premenopausal bleeding	*0*	*0.0*	*7*	*58.3*
Postmenopausal bleeding	*0*	*0.0*	*3*	*25.0*
Prolapse	*0*	*0.0*	*2*	*16.7*
Total	*22*	*100.0*	*12*	*100.0*

P<0.001*

Significant

There is significant difference between cases and controls regarding pathology.

Table(3):Comparison between study cases and controls as regards menstrual phase.

Menstrual phase	*Study Cases (N=22)*		*Controls (N=12)*	
	No.	*%*	*No.*	*%*
Secretory	*13*	*59.1*	*6*	*66.7*
Proliferative	*9*	*40.9*	*3*	*33.3*
Total	*22*	*100.0*	*12*	*100.0*

Fisher's exact test ***p>0.05***

As regards menstrual phase the two groups are well matched, and there is statistically insignificant difference between study cases and controls (P>0.05).

Table(4):Comparison between myometrium of fibroids and control myometrium as regards the mean of bcl-2.

Bcl-2	*Study myometrium (N=22)*	*Myometrium (N=12)*
Mean ±SD	*107.90 U/mg protein ± 51.59*	*77.16U/mg protein ± 48.06*
T	*1.70*	
P	*>0.05*	

Althogh there is statistically insignificant difference between study myometrium and control myometrium as regard the mean of bcl –2, may be if we use large number of cases I think that the difference become significant.

Fig.(3):The mean concentration ±SD of bcl-2 in study and control myometrium.



Table(5):Comparison between mean of bcl-2 in leiomyoma and control myometrium.

bcl-2	*Leiomyoma (N=22)*	*Control myometrium (N=12)*
Mean± SD	*296.74U/ mg protein ±114.39*	*77.16U/ mg protein ±48.06*
t	*7.83*	
p	*<0.001**	

There is statistically significant difference between the mean of bcl-2 in leiomyoma and control myometrium (P<0.001).

Fig.(4):The mean concentration±SD of bcl-2 in leiomyoma and control myometrium.



Table(6):Comparison between mean of bcl-2 in leiomyoma and myometrium of fibroids.

Bcl-2	*Leiomyoma (N=22)*	*Study myometrium N=22*
Mean ±SD	*296.74U/mg protein ±114.39*	*107.90U/mg protein ± 51.59*
t (paired)	*6.62*	
p	*<0.001**	

There is statistically significant difference between mean of bcl-2 in leiomyoma and myometrium of the same cases(P<0.001).

Fig.(5):The mean concentration ±SD of bcl-2 in study myometrium and leiomyoma.



Table(7):Comparison between mean of bcl-2 in myonetrium of fibroids in secretory and proliferative phases (N=22).

Bcl-2	*Secretory Phase (N=13)*	*Proliferative Phase (N=9)*
Mean ± SD	*114.78U/ mg protein ± 56.27*	*97.94U/ mg protein ± 45.3+*
t	*0.74*	
p	*>0.05*	

There is statistically insignificant difference between mean of bcl- in myometrium of fibroids in secretory and proliferate phases (P>0.05).

Fig.(6):The mean concentration ±SDof bcl-2 in in study myometrium in secretory and proliferative phases.



Table(8): comparison between mean of bcl-2 in Leiomyoma in secretory and proliferative phases (N=22).

Bcl-2	*Proliferative phase (N=13)*	*Secretory phase (N=9)*
Mean ± SD	*289.88 U/ mg protein ± 104.08*	*306.66 U/ mg protein ± 133.83*
t	*0.33*	
p	*>0.05*	

There is statistically insignificant difference between mean of bcl-2 in leiomyoma in secretory and proliferative phases(P>0.05)

Fig.(7):The mean concentration ±SD of bcl-2 in leiomyoma in secretory and proliferative phases.



Table(9):Comparison between mean of bcl-2 in cotrol myometrium in secretory and proliferative phases(N=12).

Bcl-2	*Secretory phase (N=9)*	*Proliferative phase (N=3)*
Mean±SD	**101.97 U/*mg protein* ± 55.31**	**45.43U/*mg protein* ±16.39**
T	*1.68*	
p	*>0.05*	

There is statistically insignificant difference between mean of bcl-2 in control myometrium in secretory and proliferative phases(P>0.05).

Fig.(8):The mean concentration±SDof bcl-2 in myometrium of controls in secretory and proliferative phases.



Table(10):Comparison between mean of bcl-2 in myometrium of fibroids in cases having single myoma and that having multiple myomas(N=22).

Bcl-2	*Single myoma (N=9)*	*Multiple myomas (N=13)*
Mean± SD	**107.88U/ *mg protein* ± 56.65**	**107.91U/ *mg protein* ± 50.19**
T	***0.01***	
p	***>0.05***	

There is statistically insignificant difference between mean of bcl-2 in myometrium of fibroids in cases having single myoma and that having multiple myomas(P>0.05).

Fig.(9):The mean concentration ±SD of bcl-2 in study myometrium in cases having single and that having multiple myomas.



Table(11):Comparison between mean of bcl-2 in Leiomyoma in cases having single myoma and that having multiple myomas(N=22).

Bcl-2	*Single myoma (N=9)*	*Multiple myomas (N=13)*
Mean ± SD	*233.99 U/ mg protein ± 113.04*	*340.18 U/mg protein ± 96.85*
t	*2.36*	
p	*<0.05**	

There is statistically significant difference between mean of bcl-2 in leiomyoma in cases having single myoma and that having multiple myomas($P<0.05$).

Fig.(10):The mean concentration ±Sdof bcl-2 in leiomyoma in cases having single and that having multiple myomas.